Tag: Neuraminidase inhibitor

In clinical trials, a single subcutaneous injection of the investigational drug CD388 was engineered to provide season-long protection against influenza. Developed by Cidara Therapeutics, CD388 represents a new class of antiviral known as a Drug-Fc conjugate (DFC), offering a different approach to traditional flu vaccines.

The CDC estimates that influenza has resulted in 9.3 million to 41 million illnesses annually in the U.S. between 2010 and 2024. When infection occurs, a key question is **what is Antiflu syrup for adults** and how can it help?

The U.S. Food and Drug Administration (FDA) approved the first generic version of Tamiflu in 2016, making a more accessible option for treating and preventing influenza widely available. The generic name of Tamiflu is oseltamivir phosphate, an antiviral medication effective against flu types A and B.

Rapivab, also known as peramivir, is an intravenous antiviral that works differently than antibiotics. Its targeted mechanism inhibits a crucial viral protein, blocking the spread of influenza throughout the body after a single dose.

First approved for public use in 1999, zanamivir (Relenza) was the first commercially available neuraminidase inhibitor specifically designed for the treatment and prevention of influenza. This antiviral medication targets a specific enzyme on the surface of the influenza virus to stop its spread. Understanding what is the mechanism of action of zanamivir relenza reveals how this targeted therapy provides a powerful defense against influenza A and B.